# Merck Reports Survival Benefit in Endometrial Cancer Trial

The company announced October 26 results for investigational sac-TMT and said the FDA accepted its application for priority review.

By Will Langan | 24X7 News
Published: 2026-10-27T05:05:48.971Z
Updated: 2026-10-27T05:05:48.971Z
Section: Health
Format: News
Canonical: https://24x7news.us/articles/merck-sac-tmt-endometrial-cancer-trial-october-2026

Launch Catch-Up — Results Announced October 26, 2026

Merck reported that its experimental medicine sacituzumab tirumotecan, or sac-TMT, improved survival against chemotherapy in a Phase 3 endometrial cancer trial.

The randomized study enrolled 776 patients with advanced or recurrent disease after platinum-based chemotherapy and anti-PD-1 or PD-L1 immunotherapy.

At a planned interim analysis, median overall survival was 19 months with sac-TMT and 12.1 months with chemotherapy, Merck said October 26. The estimated relative risk of death was 32% lower. That group-level estimate does not predict an individual patient’s outcome.

Grade 3 or higher treatment-related adverse events occurred in 54.4% of sac-TMT patients, compared with 41.4% receiving chemotherapy. Treatment-related deaths occurred in 0.8% in each group.

Merck said the FDA accepted its application for priority review and set June 15, 2027 as the target action date. Priority review is not approval. The drug remains investigational for this use in the United States, and the announcement does not establish access or suitability for individual patients.

Sources:
Merck — October 26 trial results and regulatory announcement: https://www.merck.com/news/sacituzumab-tirumotecan-sac-tmt-reduced-the-risk-of-death-by-32-and-the-risk-of-disease-progression-or-death-by-41-compared-to-chemotherapy-in-certain-patients-with-advanced-or-recurrent-endometrial/

## Sources
- Merck — October 26 TroFuse-005 trial results and priority review announcement: https://www.merck.com/news/sacituzumab-tirumotecan-sac-tmt-reduced-the-risk-of-death-by-32-and-the-risk-of-disease-progression-or-death-by-41-compared-to-chemotherapy-in-certain-patients-with-advanced-or-recurrent-endometrial/